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Introduction
HCV is one of the most relevant co-morbidities seen in
HIV-infected individuals as evidenced by the negative
impact that HIV exerts on the course of HCV infection.
Despite remarkable results on HIV infection alone, the
impact of highly active antiretroviral therapy (HAART) on
liver disease in co-infection remains unknown. We sought
to explore the impact of Raltegravir (RAL) on amino
transferase (ALT) in HIV/HCV co-infected individuals.
Methods
HIV-infected individuals co-infected with HCV within the
last 5 years receiving non-integrase inhibitor containing
HAART with a subsequent switch to RAL-containing
HAART were identified from a retrospectively maintained
outpatient database. Patient demographics were extracted.
Biochemical, virological and immunological parameters
were collated and individuals received pegylated interferon
with ribavirin were excluded. ALT levels at switch and
post switch were compared using Kruskal-Wallis test.
Spearman’s Rank correlation was used to assess the rela-
tionship between ALT and HCV-RNA.
Results
Twenty seven HIV-HCV co-infected individuals were
identified between January 2007 and January 2012 and
seven individuals were excluded. Median age was 44 years
(range: 31-68). Five had acute and fifteen had chronic
HCV infection during the switch. Twenty (100%) had
HIV-RNA-1.
Conclusion
In our study, RAL had a favourable effect on the liver
up to 24 weeks after switch in HIV/HCV infected
individuals.
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